-
Complement drugs are full of smoke! Novartis, AstraZeneca, Sanofi, Roche prepare
Time of Update: 2022-12-30
Rare diseases have always been the field of onslaught by multinational big pharmaceutical companies, and the market competition around "orphan drugs" has never lacked stories. Novartis has announced
-
In 2023, the field of innovative drugs may welcome Davis double-click, and such companies can pay attention
Time of Update: 2022-12-30
It is reported that on December 15, Innovent Biologics announced that the Group and LG Chem Life Sciences (hereinafter referred to as "LG Chem"), a subsidiary of LG Chem, have reached a strategic cooperation and licensing agreement on the late-stage clinical innovative drug Tigulixotat (LG R&D code: LC350189, Group R&D code: IBI-350), a new non-purine analogue xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia in gout patients.
-
The development direction of the pharmaceutical equipment industry is gradually clear, and the industry concentration will continue to increase!
Time of Update: 2022-12-30
The development direction of the pharmaceutical machine industry is gradually clear, and the concentration may continue to increase (Image source: Pharmaceutical Network) The development situation of the pharmaceutical equipment industry is good, and the performance of enterprises is eye-catching In the first half of 2022, the performance of many pharmaceutical equipment enterprises was red, and the revenue of Chutian Technology and Dongfulong both achieved a growth of more than 20%, and the net profit increased significantly.
-
Multinational pharmaceutical companies set off a wave of rare disease mergers and acquisitions, domestic pharmaceutical companies take orphan drugs to go to sea, Ascentage, Shiyao, Junshi ...
Time of Update: 2022-12-30
First, there are about 300 million patients with rare diseases in the world, and there are huge commercial interests in the market Due to the significant characteristics of small patient population, difficult drug research and development, and high cost, the rare disease track has always been a well-known "unpopular" and niche track, unlike anti-tumor, autoimmune and other popular tracks, attracting many pharmaceutical companies to compete and fight fiercely.
-
Pharmaceutical companies in many places are fully powered, and the circulation of drugs is accelerated - to meet the needs of the masses for drugs to the greatest extent
Time of Update: 2022-12-30
In recent days, the demand for treatment drugs after new coronavirus infection has increased significantly. The joint prevention and control mechanism of the State Council held a press conference a f
-
In December, a number of IPOs were applied for and listed in the pharmaceutical industry
Time of Update: 2022-12-30
According to the company's announcement on December 2, all the shares issued this time are new shares, the initial number of shares issued is 15 million, and the total share capital after issuance is 83.
-
New rules for marketing authorization holders open for comments! There are special requirements for the audit of pharmaceutical packaging material suppliers and the post-marketing change control system of drugs
Time of Update: 2022-12-30
In addition, Article 23 [Requirements for Drug Safety Incidents] stipulates that in the event of a safety incident related to drug quality, the holder shall immediately take effective measures to dispose of the relevant drugs and their raw materials, excipients, packaging materials and containers and relevant production lines that directly contact drugs, so as to prevent the harm from expanding.
-
Novo Nordisk Shanghai signed a contract with Shanghai Pharmaceutical Holdings The cooperation will achieve another breakthrough
Time of Update: 2022-12-30
Xiaping Zhou, Senior Vice President and President of Greater China, Novo Nordisk, said: "This investment is an important step for Novo Nordisk to realize the new layout of the 'dual center, three engines' whole industry chain, which will further strengthen the business capabilities of the trade and innovation center in Shanghai, support the development of Shanghai's pharmaceutical trade, and better serve Chinese patients.
-
The pharmaceutical sector is "hot and ice", and the valuation repair opportunity is optimistic
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];Recently, the pharmaceutical sector has performed strongly, and the "taking medicine" market has lasted for nearly two months since November, while the A-share pharmaceutical and biological sector has also recently attracted the attention of funds.
-
The new version of the tertiary hospital review pays close attention to illegal procurement and malicious insurance fraud!
Time of Update: 2022-12-30
Since the beginning of this year, the Central Commission for Discipline Inspection and the State Supervision Commission have repeatedly intensively reported on medical anti-corruption, drug kickbacks and other issues, and while medical representatives, pharmaceutical companies and other relevant personnel have been brought out, many "number one" in third-class hospitals have also fallen one after another.
-
The price of raw materials for Lianhua Qingwen has skyrocketed, and ensuring production is the top priority!
Time of Update: 2022-12-30
According to the third quarterly report of 2022 released by Shijiazhuang Yiling Pharmaceutical Co. , Ltd. (Yiling Pharmaceutical, 002603), in the first three quarters, the company achieved operating
-
Domestic pharmaceutical enterprises are vigorously promoting the construction of industrialization bases, and investment of 100 million yuan has become the norm
Time of Update: 2022-12-30
With the wave of innovation in the pharmaceutical industry, many enterprises are accelerating projects such as building new R&D production bases in order to improve profitability, enhance innovative
-
In 2022, China's innovative drug license out transactions TOP10
Time of Update: 2022-12-30
On the evening of December 6, Akeso announced that it entered into a licensing transaction cooperation with Summit for overseas rights (the United States, Europe, Japan and Canada) for PD-1/VEGF bispecific antibodies (Ewosi, AK112) with a down payment of 500 million US dollars and a total amount of up to 5 billion US dollars, which has attracted widespread attention in the industry.
-
The innovation and upgrading of medicine bag equipment has accelerated, and the development trend of automation and intelligence in the industry is obvious
Time of Update: 2022-12-30
Under the acceleration of innovation and upgrading of medicine bag equipment, the development trend of intelligence is obvious (Image source: Pharmaceutical Network) In this context, the industry generally believes that the domestic pharmaceutical packaging machine industry has both opportunities and challenges, and equipment suppliers need to keep up with the pace of the entire industry and accelerate the improvement of competitiveness.
-
The stock prices of Yiling Pharmaceutical, Northeast Pharmaceutical, Xinhua Pharmaceutical, etc. soared in December! How long can the "hoarding market" last?
Time of Update: 2022-12-30
Recently, the market demand for antipyretic and analgesic drugs has exploded, and Xinhua Pharmaceutical, the leading A-share ibuprofen API, is hot, with a stock price of 8 boards in 10 days, a five-day increase of 83.
-
The myopia drug market is just rushing to the beach, and many pharmaceutical companies have entered the market!
Time of Update: 2022-12-30
News on December 15, Xingqi Eye Medicine announced the completion of the 1-year phase III clinical trial summary report of atropine sulfate eye drops.
News on December 15, Xingqi Eye Medicine announced the completion of the 1-year phase III clinical trial summary report of atropine sulfate eye drops.
-
Pharmaceutical biology is optimistic, and these companies have been frequently investigated recently
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];In the past week, the number of listed companies surveyed by disclosed institutions reached 190 (compared to 205 in the previous week), focusing on machinery and equipment, medicine and biology, electronics, basic chemicals, computers, automobiles and other industries.
-
On the same day, a large number of domestic pharmaceutical companies announced that new drugs were approved for clinical trials and marketing
Time of Update: 2022-12-30
Enhua Pharmaceutical On December 19, Enhua Pharmaceutical announced that it had recently received the "Drug Clinical Trial Approval Notice" for Class 1 chemical NH130 citrate tablets approved and issued by the National Medical Products Administration, and will carry out clinical trials in the near future, and the indication applied for is intended for the treatment of Parkinson's disease psychiatric (PDP).
-
CDE issued four announcements, including "Technical Guidelines for Bioequivalence Research of Amphotericin B Liposomes for Injection"
Time of Update: 2022-12-30
The Drug Review Center of the State Food and Drug Administration issued the "Technical Guidelines for Bioequivalence Research of Amphotericin B Liposomes for Injection", "Technical Guidelines for Bio
-
Last week, a large number of pharmaceutical companies were reduced by shareholders
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];This year's wave of reduction is sweeping the pharmaceutical circle, and a large number of listed pharmaceutical companies are announcing the reduction of shareholders or executives one after another, including WuXi AppTec, Inco Medical, Aotai Biologics, Huasen Pharmaceutical, Aviron and so on.